Immunotherapy— A Powerful Tool in the Fight Against Cancer

Best Practices in Immunotherapy – June/July 2017 Vol 8
Lillie D. Shockney, RN, BS, MAS, ONN-CG
Editor-in-Chief, JONS; Program Director, AONN+; University Distinguished Service Professor of Breast Cancer, Administrative Director, The Johns Hopkins Breast Center; Director, John Hopkins Cancer Survivorship Programs; Professor of Surgery and Oncology, JHU School of Medicine; Co-Creator, Work Stride-Managing Cancer at Work
shockli@jhmi.edu

Dear Navigators,

On behalf of the JONS Editorial Board, it is my pleasure to present this special edition dedicated to the topic of immunotherapy. One of the many responsibilities of a navigator is to facilitate patient education—it is therefore imperative that we educate ourselves on new treatments, distill the information into lay terms, and use that information to effectively educate our patients.

I know that when patients initially receive a cancer diagnosis, among the barrage of thoughts and fears that simultaneously strike them is the assumption that they will receive chemotherapy. Whereas at one time chemotherapy was one of our only weapons in the fight against cancer, that is not true today. And while chemotherapies remain an effective tool, they are joined by other therapy options, including immunotherapies.

There are several types of immunotherapies, including monoclonal antibodies, immune checkpoint inhibitors, and therapeutic vaccines. All have the goal of empowering the body’s own immune system to fight cancer. Much of the information on immunotherapies is highly scientific in nature and presented in scholarly or academic venues, so it is important for navigators to find the correct tools to help our patients attain a thorough understanding of this therapeutic option in language that is accessible.

Immunotherapies are an important new weapon in our arsenal, and as navigators, we are obligated to learn all we can about them. I hope this issue increases your understanding of this exciting area of oncology treatment.

Sincerely,

Lillie D. Shockney, RN, BS, MAS, ONN-CG
Editor-in-Chief, JONS; Program Director, AONN+
University Distinguished Service Professor of Breast Cancer; Administrative Director, the Johns Hopkins Breast Center; Director, Cancer Survivorship
Programs at the Sidney Kimmel Cancer Center at Johns Hopkins; Professor, JHU School of Medicine, Depts of Surgery and Oncology; Cofounder, Johns Hopkins Medicine Managing Cancer at Work.
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Related Articles
Recent Approvals in Immunotherapy Options for Patients with Lung Cancer
Lavinia Dobrea, RN, MS, OCN, Timothy E Byun, MD
|
Best Practices in Lung Cancer – November 2018 Vol 9
Immunotherapy drugs work by boosting the immune system so that a person’s own immune system works smarter to identify and destroy any cancer cells.
Use of Immunotherapy Across the Continuum in Non–Small Cell Lung Cancer
Amy Jo Pixley, MSN, RN, OCN, ONN-CG
|
Best Practices in Lung Cancer – November 2018 Vol 9
The medical management landscape for non–small cell lung cancer (NSCLC) has been changing with the rapidity of the seasons. Long gone is the day when all are treated equally.
Achieving the Mission: Promoting Evidence-Based Navigation Practices
November 2018 Vol 9, NO 11

This time of year is one of great excitement for us at JONS and the Academy of Oncology Nurse & Patient Navigators (AONN+).

Last modified: June 9, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code